Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

The estimated patent date of Remicade and Rituxan

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
rwdm Member Profile
 
Followed By 2
Posts 73
Boards Moderated 0
Alias Born 07/19/10
160x600 placeholder
Putin Circumspect on Re-Election, but Critical of Western Sanctions
Russian President Vladimir Putin said he would not retain his post forever, but doesn't rule out running in 2018, and said the Western sanctions against Moscow violate human rights and are aimed at sowing discord in Russian society.
China Mobile's Need for Speed -- Barron's Asia
Zoetis Unveils $500 Million Stock Buyback Plan -- Update
Intel Projects More Growth in 2015 -- Update
Appeals Court Grants TV Programmers Stay in FCC Dispute -- Update
Technip Bids for CGG -- 2nd Update
Wireless Carriers Bid Up US Airwaves To Record
Faith-Based Shareholders Prepare Day of Reckoning for Bank of America
Chinese Premier Plays Down Qualcomm's Woes
Activision Blizzard to Get $275 Million in Settlement
rwdm   Thursday, 07/29/10 02:07:10 PM
Re: None
Post # of 184130 
The estimated patent date of Remicade and Rituxan in Europe are 2014 and 2015 respectively. In the US both expiry dates are in 2018. Is this because of Genentech's Cabily patent? If yes, does this mean that the expiry date of most of the mabs in US is 2018?

Is Teva's Rituximab TL011, which is starting nowadays clinical trials, in the regulatory pathway of BLA or as a biosimilar?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist